Lauren E. Damon

1.8k citations

21 papers · 1.2k indexed · 1 hit paper · h-index 12

Impact in

Hematology top 1%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 2%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 15
- Acute Myeloid Leukemia Research 14
- Chronic Myeloid Leukemia Treatments 11
Genetics 9
- Chronic Lymphocytic Leukemia Research 8

Co-authors: Neil P. Shah Catherine C. Smith Alexander E. Perl Sara Salerno John Kuriyan Mark J. Levis Andrew Kasarskis Kevin Travers
Journals: Blood (8 papers)Journal of Clinical Oncology (3 papers)The Journal of Heart and Lung Transplantation (1 paper)Surgical Endoscopy (1 paper)Nature (1 paper)
Partner nations: United States

In The Last Decade

Lauren E. Damon

20 papers receiving 1.2k citations

Hit Papers

align trajectories log scale

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia 2012 · 542 citations

Peers

Countries citing papers authored by Lauren E. Damon

Since Specialization

Citations

This map shows the geographic impact of Lauren E. Damon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lauren E. Damon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lauren E. Damon more than expected).

Fields of papers citing papers by Lauren E. Damon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lauren E. Damon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lauren E. Damon. The network helps show where Lauren E. Damon may publish in the future.

Co-authors

The 25 scholars most cited alongside Lauren E. Damon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lauren E. Damon Line = papers co-authored together Lauren E. Damon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Hidden Histoplasmosis: Adrenal and Central Nervous System Mycosis in an Immunocompetent Patient Cureus ·Jhanavi Oswal, Daniel Zapata Escobar, Luis Enrique Goméz Toné, G. Bagliesi, Derek J. Bays, Lauren E. Damon	2025	0
2	Gangrenous cholecystitis: innovative laparoscopic techniques to facilitate subtotal fenestrating cholecystectomy when a critical view of safety cannot be achieved Surgical Endoscopy ·K. Seine, Lauren E. Damon, Jennifer Wang, Esther Hong, Kimberly S. Kirkwood	2017	17
3	Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML) Blood ·Catherine C. Smith, Kimberly C. Lin, Elisabeth A. Lasater, Ilaria Marre, Lauren E. Damon, Andrew Kasarskis, Ali Bashir, Matthew Pendleton, Robert Sebra, Alexander E. Perl, Mai H. Le, Chao Zhang, Brian L. West, Neil P. Shah	2013	6
4	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD Blood ·Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Kimberly C. Lin, Ilaria Marre, Lauren E. Damon, Sara Salerno, Neil P. Shah	2013	101
5	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia Nature ·Catherine C. Smith, Qi Wang, Chen-Shan Chin, Sara Salerno, Lauren E. Damon, Mark J. Levis, Alexander E. Perl, Kevin Travers, Susana Wang, Jeremy P. Hunt, Patrick P. Zarrinkar, Eric E. Schadt, Andrew Kasarskis, John Kuriyan, Neil P. Shah Hit paper breakdown →	2012	542
6	Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220 Blood ·Catherine C. Smith, Shuo-feng Wang, Elisabeth A. Lasater, Amy L. Paguirigan, Kimberly C. Lin, Ilaria Marre, Sara Salerno, Lauren E. Damon, Mark J. Levis, Alexander E. Perl, Kevin Travers, Andrew Kasarskis, Jerald P. Radich, Neil P. Shah	2012	4
7	Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants Blood ·Catherine C. Smith, Elisabeth A. Lasater, Melissa Q. McCreery, Kimberly C. Lin, Ilaria Marre, Lauren E. Damon, Alexander E. Perl, Grace R. Jeschke, Mayumi Sugita, Martin Carroll, Scott C. Kogan, Neil P. Shah	2012	14
8	Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants Blood ·Catherine C. Smith, Lauren E. Damon, Xiaotian Zhu, Sara Salerno, Neil P. Shah	2011	1
9	Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 Haematologica ·Hui Liu, Jeffrey L. Johnson, Anil Singh, Gregory Malnassy, Dorie Sher, Lauren E. Damon, Eric D. Hsi, Donna Bucci, Claudia Linker, Bruce D. Cheson, Wendy Stock	2011	59
10	Abstract 4737: Saturation mutagenesis of FLT3-ITD: AC220-resistance-conferring kinase domain mutations are restricted to a limited number of residues and are cross-resistant to sorafenib in vitro Cancer Research ·Catherine C. Smith, Lauren E. Damon, Sara Salerno, Neil P. Shah	2011	1
11	Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia Blood ·Catherine C. Smith, Shuo-feng Wang, Qi Wang, Sara Salerno, Lauren E. Damon, Jeremy P. Hunt, Mark J. Levis, Alexander E. Perl, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric E. Schadt, John Kuriyan, Neil P. Shah	2011	4
12	Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations Blood ·Warren Fiskus, Catherine C. Smith, Jacqueline Smith, Scott Wise, Elisabeth A. Lasater, Lauren E. Damon, Sara Salerno, Carolina Mendoza Fuentes, Ruben Reyes, Siddhartha Ganguly, Mark S. Berger, Pablo Colomina Torregrosa, Joseph P. McGuirk, Neil P. Shah, Kapil N. Bhalla	2011	3
13	PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro Blood ·Catherine C. Smith, Alexander E. Perl, Elisabeth A. Lasater, Chao Zhang, Grace R. Jeschke, Lauren E. Damon, Martin Carroll, Neil P. Shah	2011	8
14	Increased CD62e+ Endothelial Microparticle Levels Predict Poor Outcome in Pulmonary Hypertension Patients The Journal of Heart and Lung Transplantation ·Nicolas Amabile, Christian Heiß, Vivian Y. Chang, Franca S. Angeli, Lauren E. Damon, J. Eduardo Rame, Dana McGlothlin, William Grossman, Teresa De Marco, Yerem Yeghiazarians	2009	89
15	Mobilization of hematopoietic stem cells into the peripheral blood Expert Review of Hematology ·Lloyd E. Damon, Lauren E. Damon	2009	22
16	Vaccine-associated immune and WT-1 responses are associated with better relapse-free survival in patients with AML in remission treated with a GM-CSF secreting leukemia vaccine and autologous stem cell transplant (ASCT) Journal of Clinical Oncology ·Ivan Borrello, Hyam I. Levitsky, Lauren E. Damon, Claudia Linker, F Barwick, Edwin P. Alyea, Wendy Stock, Dorie Sher, Takuya Toda, Kristen Hege	2005	4
17	High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. Journal of Clinical Oncology ·Martha Cecilia Paspuel Narváez, Lauren E. Damon, Hope S. Rugo, Curt A. Ries, Claudia Linker	1997	55
18	Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. PubMed ·Lauren E. Damon, H. S. Rugo, Curt A. Ries, CA Linker	1994	15
19	The association between high-dose cytarabine neurotoxicity and renal insufficiency. Journal of Clinical Oncology ·Lauren E. Damon, R. Mass, Claudia Linker	1989	43
20	Cytotoxicity of ketoconazole in malignant cell lines Cancer Chemotherapy and Pharmacology ·Christoph Rochlitz, Lauren E. Damon, M Russi, Javier Humberto Rubio Plazas, Ed Cadman	1988	37

About Lauren E. Damon

Lauren E. Damon is a scholar working on Hematology, Genetics, Oncology, Small Animals and Pharmacology, having authored 21 papers that have together received 1.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (8 papers), Cancer Treatment and Pharmacology (3 papers), Pharmacological Effects and Toxicity Studies (2 papers), Extracellular vesicles in disease (1 paper), CAR-T cell therapy research (1 paper) and Antifungal resistance and susceptibility (1 paper). The work is most often cited by research in Hematology (782 citations), Genetics (401 citations), Molecular Biology (536 citations), Oncology (199 citations) and Cancer Research (103 citations). Lauren E. Damon has collaborated with scholars based in United States. Frequent co-authors include Neil P. Shah, Catherine C. Smith, Alexander E. Perl, Sara Salerno, John Kuriyan, Mark J. Levis, Andrew Kasarskis, Kevin Travers, Susana Wang and Qi Wang. Their work appears in journals such as Blood, Journal of Clinical Oncology, The Journal of Heart and Lung Transplantation, Surgical Endoscopy and Nature.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact